Mechanistic Assessment of Norepinephrine Therapy versus Angiotensin-II in Septic Shock (MANTRA): Study Protocol for a multicenter randomized trial
- 1Massachusetts General Hospital
Abstract
IntroductionNorepinephrine remains first-line vasopressor therapy for septic shock despite its association at high doses with undesirable cardiovascular, kidney, and immune effects. Angiotensin-II (Ang-II) is a non-catecholamine vasopressor of the renin-angiotensin-aldosterone system (RAAS) now approved to increase blood pressure in vasodilatory shock. RAAS dysregulation is common in septic shock and may represent a treatable trait. However, few prospective investigations evaluate the effect of early Ang-II use in septic shock on dysfunctional RAAS biology, host-response, or clinical outcomes. Therefore, we designed a mechanistic clinical trial to test the hypothesis that early Ang-II therapy in septic shock normalizes systemic RAAS abnormalities and modulates innate immune responses.
Methods and AnalysisThe Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) trial is an investigator-initiated, prospective, multicenter, open-label, randomized mechanistic clinical trial. Adults with septic shock by Sepsis-3 criteria receiving a norepinephrine-equivalent dose (NED) of 0.10-0.50 mcg/kg/min will be randomized 1:1 to primary Ang-II (to a maximum of 40 ng/kg/min) or norepinephrine (to a maximum 35 mcg/min) treatment strategies over a 48-hour period. The primary outcome is the between-group difference in plasma renin trajectory from baseline to 24 hours, analyzed using a linear mixed-effects model with a treatment-by-time interaction term. With n=78, the trial has 90% power (at two-sided =0.05) to detect a 25% between-group difference in 24-hour renin. Secondary clinical outcomes include longitudinal NED, hours alive and vasopressor-free at 72 hours, a 28-day composite outcome (days alive and free of vasopressors, renal replacement therapy, and mechanical ventilation), treatment failure requiring crossover or protocol discontinuation, and thrombotic and arrhythmia events through 28 days. Secondary mechanistic outcomes include serial RAAS biomarkers (prorenin, soluble prorenin receptor, angiotensinogen, ACE, ACE2, Ang-II, angiotensin-(1-7), aldosterone, and DPP3), immune measures (ex vivo monocyte function, monocyte gene expression, plasma cytokines), and organ injury biomarkers. Enrollment is planned from 5/2026-7/2030.
Strengths and limitations of this studyO_LIMANTRA is a randomized trial comparing angiotensin-II against an active standard-of-care norepinephrine strategy rather than placebo, enrolling patients earlier in septic shock than prior trials restricted to catecholamine-resistant shock. C_LIO_LISerial sampling profiles RAAS peptides, innate immune function, and organ-injury biomarkers, which will generate rich mechanistic data on how vasopressor strategy shapes the host response. C_LIO_LIThe sample size is adequate for the biomarker primary endpoints and will establish feasibility for a larger trial, but it does not provide sufficient power for hard clinical endpoints, which remain exploratory. C_LIO_LIMANTRA compares two open-label vasopressor strategies rather than monotherapies; clinician retain discretion over background and rescue vasopressors, steroids, and crossover, which may attenuate differences between-arms. C_LIO_LIThe 48-hour intervention window limit inference about clinician-assessed outcomes and the durability of treatment effect. C_LI
Related
- Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.
- Efficacy and safety of Anas barbariae 200K in influenza-like illness: a randomized double-blind, placebo-controlled, multicenter study
- Evaluation of the efficacy of duloxetine and venlafaxine in chemotherapy-induced neuropathy in cancer patients: a double-blind multicenter randomized clinical trial
- DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo Controlled Crossover Trial
- CT-based AI risk support for cystic renal masses: multicenter validation, reader study, and a randomized implementation study
BibTeX
@misc{filbin2026mechanistic,
title = {{Mechanistic Assessment of Norepinephrine Therapy versus Angiotensin-II in Septic Shock (MANTRA): Study Protocol for a multicenter randomized trial}},
author = {M. Filbin and D. E. Leisman and A. Pachano-Bravo and M. B. Goldberg and K. A. Hibbert and O. Nelson and B. Rappaport and S. A. Mahler and L. Harris and E. B. Besong and B. Reeves and R. C. Maves and A. Petrilli and C. L. Schaich and D. C. Files and K. Gibbs and M. C. Chappell and A. K. Khanna},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.12.26362906},
url = {https://www.medrxiv.org/content/10.64898/2026.09.12.26362906v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Mechanistic Assessment of Norepinephrine Therapy versus Angiotensin-II in Septic Shock (MANTRA): Study Protocol for a multicenter randomized trial
AU - M. Filbin
AU - D. E. Leisman
AU - A. Pachano-Bravo
AU - M. B. Goldberg
AU - K. A. Hibbert
AU - O. Nelson
AU - B. Rappaport
AU - S. A. Mahler
AU - L. Harris
AU - E. B. Besong
AU - B. Reeves
AU - R. C. Maves
AU - A. Petrilli
AU - C. L. Schaich
AU - D. C. Files
AU - K. Gibbs
AU - M. C. Chappell
AU - A. K. Khanna
PY - 2026
DA - 2026/09/12
PB - medRxiv
DO - 10.64898/2026.09.12.26362906
UR - https://www.medrxiv.org/content/10.64898/2026.09.12.26362906v1
AB - IntroductionNorepinephrine remains first-line vasopressor therapy for septic shock despite its association at high doses with undesirable cardiovascular, kidney, and immune effects. Angiotensin-II (Ang-II) is a non-catecholamine vasopressor of the renin-angiotensin-aldosterone system (RAAS) now approved to increase blood pressure in vasodilatory shock. RAAS dysregulation is common in septic shock and may represent a treatable trait. However, few prospective investigations evaluate the effect of early Ang-II use in septic shock on dysfunctional RAAS biology, host-response, or clinical outcomes. Therefore, we designed a mechanistic clinical trial to test the hypothesis that early Ang-II therapy in septic shock normalizes systemic RAAS abnormalities and modulates innate immune responses. Methods and AnalysisThe Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) trial is an investigator-initiated, prospective, multicenter, open-label, randomized mechanistic clinical trial. Adults with septic shock by Sepsis-3 criteria receiving a norepinephrine-equivalent dose (NED) of 0.10-0.50 mcg/kg/min will be randomized 1:1 to primary Ang-II (to a maximum of 40 ng/kg/min) or norepinephrine (to a maximum 35 mcg/min) treatment strategies over a 48-hour period. The primary outcome is the between-group difference in plasma renin trajectory from baseline to 24 hours, analyzed using a linear mixed-effects model with a treatment-by-time interaction term. With n=78, the trial has 90% power (at two-sided =0.05) to detect a 25% between-group difference in 24-hour renin. Secondary clinical outcomes include longitudinal NED, hours alive and vasopressor-free at 72 hours, a 28-day composite outcome (days alive and free of vasopressors, renal replacement therapy, and mechanical ventilation), treatment failure requiring crossover or protocol discontinuation, and thrombotic and arrhythmia events through 28 days. Secondary mechanistic outcomes include serial RAAS biomarkers (prorenin, soluble prorenin receptor, angiotensinogen, ACE, ACE2, Ang-II, angiotensin-(1-7), aldosterone, and DPP3), immune measures (ex vivo monocyte function, monocyte gene expression, plasma cytokines), and organ injury biomarkers. Enrollment is planned from 5/2026-7/2030. Strengths and limitations of this studyO_LIMANTRA is a randomized trial comparing angiotensin-II against an active standard-of-care norepinephrine strategy rather than placebo, enrolling patients earlier in septic shock than prior trials restricted to catecholamine-resistant shock. C_LIO_LISerial sampling profiles RAAS peptides, innate immune function, and organ-injury biomarkers, which will generate rich mechanistic data on how vasopressor strategy shapes the host response. C_LIO_LIThe sample size is adequate for the biomarker primary endpoints and will establish feasibility for a larger trial, but it does not provide sufficient power for hard clinical endpoints, which remain exploratory. C_LIO_LIMANTRA compares two open-label vasopressor strategies rather than monotherapies; clinician retain discretion over background and rescue vasopressors, steroids, and crossover, which may attenuate differences between-arms. C_LIO_LIThe 48-hour intervention window limit inference about clinician-assessed outcomes and the durability of treatment effect. C_LI
ER -